Amalgamated Bank Sells 1,201 Shares of Lantheus Holdings, Inc. (NASDAQ:LNTH)

Amalgamated Bank lessened its position in Lantheus Holdings, Inc. (NASDAQ:LNTH) by 3.8% during the first quarter, Holdings Channel.com reports. The fund owned 30,580 shares of the medical equipment provider’s stock after selling 1,201 shares during the period. Amalgamated Bank’s holdings in Lantheus were worth $2,985,000 at the end of the most recent quarter.

A number of other large investors have also added to or reduced their stakes in LNTH. Janus Henderson Group PLC grew its holdings in Lantheus by 72.7% in the 4th quarter. Janus Henderson Group PLC now owns 6,198,689 shares of the medical equipment provider’s stock worth $554,583,000 after acquiring an additional 2,610,118 shares during the last quarter. Farallon Capital Management LLC boosted its stake in shares of Lantheus by 79.9% during the 4th quarter. Farallon Capital Management LLC now owns 5,316,227 shares of the medical equipment provider’s stock valued at $475,590,000 after purchasing an additional 2,361,000 shares in the last quarter. T. Rowe Price Investment Management Inc. boosted its stake in shares of Lantheus by 40.5% during the 4th quarter. T. Rowe Price Investment Management Inc. now owns 1,509,332 shares of the medical equipment provider’s stock valued at $135,025,000 after purchasing an additional 435,445 shares in the last quarter. Raymond James Financial Inc. bought a new stake in shares of Lantheus during the 4th quarter valued at about $36,183,000. Finally, Assenagon Asset Management S.A. boosted its stake in shares of Lantheus by 1,196.4% during the 1st quarter. Assenagon Asset Management S.A. now owns 336,237 shares of the medical equipment provider’s stock valued at $32,817,000 after purchasing an additional 310,301 shares in the last quarter. Institutional investors own 99.06% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts have recently weighed in on the stock. Truist Financial cut their target price on shares of Lantheus from $127.00 to $117.00 and set a “buy” rating on the stock in a research note on Thursday, May 8th. B. Riley cut their target price on shares of Lantheus from $122.00 to $109.00 and set a “buy” rating on the stock in a research note on Monday, June 23rd. Finally, Wall Street Zen raised shares of Lantheus from a “hold” rating to a “buy” rating in a research note on Thursday, May 8th. Seven investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Lantheus has a consensus rating of “Buy” and a consensus price target of $130.50.

Lantheus Price Performance

LNTH stock opened at $79.21 on Friday. The firm has a 50 day moving average price of $82.57 and a 200-day moving average price of $90.25. Lantheus Holdings, Inc. has a 52-week low of $73.11 and a 52-week high of $126.89. The firm has a market capitalization of $5.48 billion, a price-to-earnings ratio of 22.50 and a beta of 0.12. The company has a debt-to-equity ratio of 0.49, a quick ratio of 5.46 and a current ratio of 5.74.

Lantheus (NASDAQ:LNTH) last released its earnings results on Wednesday, May 7th. The medical equipment provider reported $1.53 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.64 by ($0.11). Lantheus had a net margin of 16.55% and a return on equity of 36.99%. The business had revenue of $372.76 million for the quarter, compared to analysts’ expectations of $377.37 million. During the same quarter in the previous year, the business posted $1.69 earnings per share. Lantheus’s revenue for the quarter was up .8% on a year-over-year basis. Equities research analysts forecast that Lantheus Holdings, Inc. will post 6.01 EPS for the current fiscal year.

Insider Activity

In related news, Director Mary Anne Heino sold 26,066 shares of the firm’s stock in a transaction that occurred on Monday, June 2nd. The shares were sold at an average price of $76.83, for a total transaction of $2,002,650.78. Following the completion of the sale, the director owned 318,650 shares of the company’s stock, valued at $24,481,879.50. This trade represents a 7.56% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 1.50% of the company’s stock.

Lantheus Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.